Last reviewed · How we verify

ropivacaine (Naropin)

University of Zurich · FDA-approved active Small molecule

ropivacaine (Naropin) is a Local anesthetic (amide) Small molecule drug developed by University of Zurich. It is currently FDA-approved for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia. Also known as: Naropin.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.

At a glance

Generic nameropivacaine (Naropin)
Also known asNaropin
SponsorUniversity of Zurich
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and nerve impulse transmission. This results in local anesthesia in the area where it is administered. It is a long-acting amide local anesthetic with a lower cardiotoxicity profile compared to bupivacaine.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ropivacaine (Naropin)

What is ropivacaine (Naropin)?

ropivacaine (Naropin) is a Local anesthetic (amide) drug developed by University of Zurich, indicated for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.

How does ropivacaine (Naropin) work?

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

What is ropivacaine (Naropin) used for?

ropivacaine (Naropin) is indicated for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.

Who makes ropivacaine (Naropin)?

ropivacaine (Naropin) is developed and marketed by University of Zurich (see full University of Zurich pipeline at /company/university-of-zurich).

Is ropivacaine (Naropin) also known as anything else?

ropivacaine (Naropin) is also known as Naropin.

What drug class is ropivacaine (Naropin) in?

ropivacaine (Naropin) belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is ropivacaine (Naropin) in?

ropivacaine (Naropin) is FDA-approved (marketed).

What are the side effects of ropivacaine (Naropin)?

Common side effects of ropivacaine (Naropin) include Hypotension, Bradycardia, Nausea, Headache, Back pain, Systemic toxicity (CNS and cardiac effects at high doses).

What does ropivacaine (Naropin) target?

ropivacaine (Naropin) targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related